CClinicalTrials.gg
Sign In
WithdrawnNCT02056613Updated Nov 5, 2018

Blood Collection From Healthy Volunteers and Patients for the Production of Clinical Grade Induced Pluripotent Stem Cell (iPSC) Products

An observational study in Induced Pluripotent Stem Cells, sponsored by National Institutes of Health Clinical Center (CC). Withdrawn. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-05.

Sponsored by National Institutes of Health Clinical Center (CC) · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
0
Ages
18 Years and older
Sex
All
01

Study summary

Background:

  • Pluripotent stem cells are cells that can be converted to any type of cell (muscle, nerve, liver, etc.). Researchers are collecting blood samples to develop way to make a special cell product called induced pluripotent stem cells (iPSCs). iPSCs may be used to repair or replace organs and tissues, produce blood and immune cells for transfusion, or correct inherited immune and blood diseases. iPSCs can be made from many kinds samples, such as skin, blood, or hair. This is different from embryonic stem cells, which can only be derived from embryos.

Objectives:

  • To develop new methods to make iPSCs; to identify better ways to collect, produce, and grow them; and to make an iPSC bank.

Eligibility:

  • Healthy adults and adults already in a treatment protocol who have a medical condition that could be treated with iPSCs.

Design:

  • All participants will be screened with questionnaire, physical exam, and blood and HIV tests.
  • All participants:
  • Will donate 4 tablespoons of blood. It will be taken by needle from a vein in their arm.
  • Participants already in another protocol:
  • Will have their blood collected, separated in a lab, and iPSCs grown in large numbers. Some may have their sample given back to them as a treatment.
  • Samples will be kept in the study up to 5 years or until a participant withdraws from the study or becomes ineligible to participate, or the study is closed. If participants have not withdrawn their consent, they may be contacted in the future to donate again.
Read the detailed description

Induced pluripotent stem cells (iPSCs) can be produced from small quantities of blood. Clinical protocols to treat several diseases using iPSCs or cells derived from iPSCs are being developed by intramural investigators, i.e., investigators in National Institute of Allergy and Infectious Diseases (NIAID) and National Eye Institute (NEI). This clinical protocol will allow personnel in the Cell Processing Service (CPS) of the Department of Transfusion Medicine (DTM) to collect blood from healthy donors or patients with diseases targeted in IRB-approved treatment protocols to manufacture iPSCs or iPSC derived products to support these intramural investigators. CPS DTM will submit a Drug Master File (DMF) to the US Food and Drug Administration (FDA) for the manufacture and testing of these products. When iPSCs are used clinically in some cases the donors will be the recipients of the iPSCs, or the ex vivo expanded and differentiated iPSCs (autologous therapy). In other cases, healthy subjects will serve as donors of the blood used as starting material for manufacturing iPSCs (allogeneic therapy) where no matching of HLA or other antigens is required between the healthy blood donor and the iPSC recipient. While methods to produce and expand iPSCs have been described, they must be modified periodically to meet changing Good Manufacturing Practices (GMP) requirements for manufacturing clinical cell and gene therapies, therefore peripheral blood for iPSCs from normal donors is needed for research and development.

02

Conditions studied

  • Induced Pluripotent Stem Cells

Keywords

  • Blood Donation
  • Tissue Procurement
  • Cellular Therapies
03

In context

Lead sponsor

National Institutes of Health Clinical Center (CC) is the lead sponsor of 367 studies on the registry; 27 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 18 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  • INCLUSION CRITERIA RELATED OR THIRD PARTY DONORS (ALLOGENEIC CELLS, INCLUDING RESEARCH DONORS) AND AUTOLOGOUS DONORS

Subjects who meet ALL of the following criteria will be considered for enrollment into this study:

  1. Be greater than or equal to 18 years of age, as of the date of enrollment. There is no upper age limit for donor enrollment.
  2. Able to provide informed consent.
  3. Meets the donation requirements established by AABB and FDA for allogeneic or autologous use with the exception of hemoglobin/hematocrit.

SUBJECT EXCLUSION CRITERIA ALLOGENEIC DONORS

Subjects who meet ANY of the following criteria will be excluded from participation in this study as a third party donor or research volunteer:

  1. Medical history that includes any of the following, as per AABB or FDA requirements for allogeneic use:

    • Thrombocytopenia or other blood dyscrasias
    • Bleeding diathesis
    • Antibiotic use within the prior 48 hours
    • History of cancer
    • History of exposure to transfusion transmitted diseases including HIV and hepatitis B and C as defined by the Standards for Blood Banking and Transfusion Services, AABB.
    • Travel to an area where malaria is endemic as defined by the CDC (www.cdc.gov/travel).
    • At risk for the possible transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) as described in the FDA Guidance for Industry, January 9, 2002, Revised Preventive Measures to Reduce the Possible Risk of Transfusion of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products
  2. Febr le (temperature >38 (Infinite)C)

  3. Hemoglobin level

    • African American women \<11.5 grams/dL
    • Other women \<12.0 grams/dL
    • Men \<12.5 grams/dL

  4. HCT

    • African American women \<34%
    • Other women \<36%
    • Men \<38%
  5. Platelets \<150 times 103/microL
  6. Absolute neutrophil count \<1.0 times 103/microL
  7. Positive tests for blood borne pathogens (as required by the Standards for Blood Banks and Transfusion Services, AABB. The currently required tests include anti-HIV1/2, anti-HCV, anti-HBc, Anti-HTLV I/II, anti-T. Cruzi, HBsAg, syphilis, and molecular testing for West Nile virus, HCV, HBV, and HIV-1).

SUBJECT EXCLUSION CRITERIA AUTOLOGOUS DONORS

Subjects who meet ANY of the following criteria will be excluded from participation in this study:

  1. Positive tests for anti-HIV1/2, anti-HCV, or HBsAg
  2. Does not meet criteria established by the NIH IRB-approved treatment protocol for administration of iPSCs, as created by the protocol PI.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
0 participants (actual)
06

What researchers measure

Primary outcomes

  1. collection of blood samples for production of iPSCs or iPSV-derived therapy products

    Time frame: Ongoing

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006 Aug 25;126(4):663-76. doi: 10.1016/j.cell.2006.07.024. Epub 2006 Aug 10. PubMed 16904174 ↗
  • Mostoslavsky G. Concise review: The magic act of generating induced pluripotent stem cells: many rabbits in the hat. Stem Cells. 2012 Jan;30(1):28-32. doi: 10.1002/stem.742. PubMed 21948613 ↗
  • Somers A, Jean JC, Sommer CA, Omari A, Ford CC, Mills JA, Ying L, Sommer AG, Jean JM, Smith BW, Lafyatis R, Demierre MF, Weiss DJ, French DL, Gadue P, Murphy GJ, Mostoslavsky G, Kotton DN. Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells. 2010 Oct;28(10):1728-40. doi: 10.1002/stem.495. PubMed 20715179 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02056613
Lead sponsor
National Institutes of Health Clinical Center (CC)
Responsible party
Sponsor
First posted
Feb 6, 2014
Start date
Feb 5, 2014
Primary completion
Nov 1, 2018
Completion
Nov 1, 2018
Last update
Nov 5, 2018

Study contacts

David F Stroncek, M.D.
principal investigator · National Institutes of Health Clinical Center (CC)
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

National Institutes of Health Clinical Center (CC)

Start the discussion